Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer

Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation IL2 agents designed to improve tolerability are in...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisner, Joel R., Beebe, Kirk D., Mayhew, Gregory M., Shibata, Yoichiro, Guo, Yuelong, Farhangfar, Carol, Farhangfar, Farhang, Uronis, Joshua M., Mooney, Jill, Milburn, Michael V., Foureau, David, White, Richard L., Amin, Asim, Milla, Marcos E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010312/
https://www.ncbi.nlm.nih.gov/pubmed/36923304
http://dx.doi.org/10.1158/2767-9764.CRC-21-0153

Ejemplares similares

Ejemplares similares